	Update	es to Utilizatio	on Management or Prior Authorization Criteria
Changes For	Drug/Class Oxyley Barlefel sun	Effective Date 6/1/2022	Ozertvírou Adding to the formulary with PA (if > 9 years old)
	Rineq	6/1/2022	Adding Lifcorative Colinis Indication to PA form
	Finteola Sysparca	6/1/2022 6/1/2022	Adding Lennos-distruct fundrome indication to PA form Adding new Innext Cancer indication to PA form
	Hepatitis C Agents (sofosbasin/velgatassin	6/1/2022	Updating PA criteria so align with steasment guidelines
	(Epclusa equiv), ledicasuir hofodouir (Hansoni equiv),	4/1/2022	произонд их споита за зеден имп пиналения дишинения
April-12	(Karvoni equiv), Mavyret, Vosevi) Humira	6/1/2022	Remainire dae through traditional DMARbs for Crobh's and OC indications to allies with treatment publishes. Remaining daep through traditional DMARbs for Crobh's and OC indications to slight with treatment publishes.
	Stelara Topical androgen products (Androgel,	6/1/2022 5/06/0022	Remaking case through traditional DMARDs for Croths's and ut-indications to align with treatment guidelines
	ropica androgen product (Androgen, Androdenn, Asinos, Testim, testingterone) Wilbrud	6/1/2022	Regulating the value responses was promote austrances for the same Removing marrislar consistences from the form
	Promacta Doptelet	6/1/2022 6/1/2022	Benobioles sectialist resultament from PA form Adding continuation orbitals for orbital innuise thromborytopenia Adding continuation orbitals for orbital innuise thromborytopenia
	Tavalicse Cortaeor	6/1/2022 6/1/2022	Adding continuation criteria for chronic immune thrombocytoperia Adding PA criteria for inappropriane sinus tachycardia and posturali orrhostaric tachycardia syndrome
Changes For	Crais (tadalafil) 2.5mg.	Effective Date 3/1/2022	Overview Replacing M with Step Therapy requirement
May-22	Sing Norlique	7/1/2022	Adding to the formulary with PA (if > 6 years old)
Changes For	Donepeol Drug/Class	7/1/2022 Effective Date	Removing Step Therapy requirement Overview
sure-32	Skytrofa Tavneos	7/1/2022 7/1/2022 7/1/2022	Adding to the formulary with PA Adding to the formulary with PA Adding to the formulary with PA
	Voxaceo Prevenis	7/1/2022 7/1/2022	Adding to the formulary with PA Adding to the formulary with PA Adding to the formular with PA
Changes For	Drug/Class Amodefini	Effective Date 8/1/2022	Overview Removing Rs.
	Modefinil Akind 0.5mg, Ling	8/1/2022 8/1/2022	Barrowine Mt
ady-22	Visica Swissah	9/1/2022 9/1/2022	Adding to the formulary with PA (if > 9 years old) Adding to the formulary with PA Adding to the formulary with PA Adding to the formulary with PA
	Kinsoq Empaveli	7/28/9022 8/1/2022	Adding Anilylosing Spondylitis Indication to PA form Updating PA form to clarify criteria and align with guidelines
	Humira Srivedge	8/1/2022 8/1/2022	conditions Uneritis PA criteria to allow for first-line use in swene cases Removing cosp through Odomos (conidegib)
Changes For	Stelara	9/1/2022	Overview Updating RA form for Ulcerative Colinic continuation criteria to account for Its formulation
	Neviragine ER Tyxasa	9/1/2022 9/1/2022	Removing (top Thropy requirement Adding no the formulary with PA Adding new formulation to the formulary with PA and adding or their is disease indication to the form.
Augus 22	Skyrizi Smolwee	9/1/2022 9/1/2022	Adding new indication to PA form for obects due to earlied conditions retain
	Tarlinlar/Mekinig CGMs (Descom, Resemble Libre)	9/1/2022 9/1/2022	Adding new indication to PA form for solid turnors with the BRAF Visibilit mutation Removing three provider attestation-related criteria from PA form
	Ayrangue Xultophy	10/15/0022 9/1/2022	updaring PA criteria to align with recent guideline updates on patient age and disease progression Updaring PA approval duration to lifetime
	Solicus Nedyta	9/1/2022 9/1/2022	Liadarána PA acoronal duration to lifetime Changing 'high-risk of recurrence' PA criteria to simply a provider attentation and adding continuation PA criteria
	pyrimethamine Fornalyst	10/15/0022 9/1/2022	opdating PA criteria to align with guidelines, which requires use with inucovarin for certain diagnoses Adding new indication to PA form for Kaposi carcoma
Changes For	Rubraca Drug/Class	Strective Date	Removing withdrawn indication from Rt Sorm for recurrent BRCA mutated advanced ovarian cancer Overview
	Freedyle Libre 3 Sensor Olumiant	10/1/2022	Adding new strength to formulary with PA and adding indication for Alopeda Areata to PA form
September-22	Xalkari Genotogin - Adult	9/15/0022 10/1/0022	About one cheeft to brimbary with M and about elections for Allipse but have to Andrew Adding ever indication for Missimutatory Myssifierablastic Turns (1911) to PA from Adding ever indication for Missimutatory Myssifierablastic Turns (1911) to PA from the align with guideliner, removing age requirement for other bowel spedicine, and removing adherence criterion. Updating PA from the align with guideliner, removing age requirement for other bowel spediciner, and removing adherence criterion.
	Genotropin - Pediatric	10/1/2022	Updating PA form to align with guidelines and removing adherence criterion
Changes For	Drug/Class Lidencity	Effective Date 16/1/2022	Overview Adding to formulary with PA Adding to formulary with PA
	Puruland Vorgo	10/1/0022	Adding to formularly with PA. Adding to formularly with PA. Adding to formularly with PA. Removing level of reverby requirement from Adoption areastors PA coloring, updating Archina PA colorina to a sign with guidelines on
0:00ber-22	Dupixent Adbry	10/1/2022	controller medications, and adding final naphilic floophagitic indication to PA form Adding to formulary with PA
	Rinseq Cibinee	10/1/2022	Removing level of severity requirement from Asopic Dermotisis PA criteria Adding to formulary with PA.
	Xobir Nacala	16/1/2022	Updating Asthma PA criteria to alige with guidelines on controller medications. Updating Asthma PA criteria to alige with guidelines on controller medications.
Changes For	Crug/Class	16/1/2022 Effective Date	updating Arthria PA criteria to align with guidelines on controller medications Overview
November 22	Opoelura Nubeqa	11/1/2022	Adding new indication to PA form for the topical treatment of nonsegmental violigio Adding new indication to PA form for the treatment of metacotic hormone-emotive prostone-cancer
Modernan G2	Benlytta	11/1/2022	updating PA criteria to require additional documentation to support diagnosis Updating PA criteria to remove the requirement of contionatorials use and so better align with guidelines.
Changes For	Drug/Class	Effective Date	Opadning PA citievia to align with MCDN guidelines Overview Adding to formulary with PA
	Zoniade Orkanbi	12/1/2022 12/1/2022 12/1/2022	reasing on formality with PA. Adding to formality with PA. Removing age requirement from PA form
	Imbrusica (aranuled)	12/1/2022	Adding to formulary with FA
December-22	Myfembree Stelara	12/1/2022 12/1/2022 12/1/2022	Adding new indication for myeloid/hymphoid enoplasms. Adding new indication for endomenticus Updating weight requirements. Adding new indication for endoments.
	Retevino Promacta	12/1/2022 2/1/2023	Adding new indication for solid tumors and updating the indication for NiCLC Updating prescriber requirement for immune thromboxytopenia
Changes For	Exhriet Drug/Class	13/1/2022 Effective Date	Updating diagnosis criteria to allow use of transbroschial lung cryobiopsy Overview
	CAMZYOS CAP RADICAVA CAS STARTER KIT	1/1/2023	Adding to formulary with PA. Adding to formulary with PA.
January-23	RADICAWA ORS SUSP	1/1/2023	Adding to formulary with PA Adding to formulary with PA
Innuary-29	2TALMY SUSP DESCOVY TAB	1/1/2023	Add criterion for severa adverse event other than bone or netal AS
	OFFICER		
	OFFY CAP SOLIDUA IN	3/1/2023 1/1/2023	Adding one shrough pirteridate Removing PA Removing PA
Changes For	OFFY CAP	3/1/2023 3/1/2023 5/1/2023 Effective Date	Removing PA. Removing PA. Overofiles Adding to formulary with PA.
	SOLICIAN SOLICIA IN XULTOPHY IN	3/1/2023 3/1/2023 5/1/2023 Effective Date	Removing PA. Removing PA. Overofiles Adding to formulary with PA.
Changes For Febary-28	SCHOOL IN SCHOOL IN XULTORY IN Drug/Class siderall susp REVATIO susp	3/1/2028 2/1/2028 2/1/2028 Effective Cano 2/1/2028 2/1/2028 2/1/2028	Anneany M. Committee Antique la brinday on M. Antique la control on
	OFFY CAP SOLITORY IN SOLITORY	8/1/2023 1/1/2023 1/1/2023 Effective Date 2/1/2023 2/1/2023 2/1/2023	Learning M. Secretary M. Making the best of particular and the secretary and the s
February-23	OFFY CAP SOLITION IN SOLITION IN SOLITION IN DIVIDING SUBJECT	8/1/2028 8/1/2028 8/1/2028 Effective Date 2/1/2028 2/1/2028 2/1/2028 2/1/2028 2/1/2028 2/1/2028 2/1/2028	Tenning M. Benome M. Personne M. Personne M. Personne M. Adding two relations to the tension of the desired many desi
February 22 Changes For	OFFY CAP SOLECUL IN SOLECUL IN SOLECUL IN SOLECUL IN SOLECUL IN SOLECUL IN SOLECUL SOL	2/1/2021 2/1/2022 2/1/2022 2/1/2022 2/1/2022 2/1/2022 2/1/2022 2/1/2022 2/1/2022 2/1/2022 2/1/2022 2/1/2022 2/1/2022 2/1/2022	Tenning III. A bening III. Book to the second III. A bening the second III. Bening t
February 22 Changes For	OFFY CAP SECSION IN AUXTORY ON AUXTORY ON ORDERSTAN ORDE	#1,0002 91,0002 91,0002 6ffective Cate 21,0002	The record of the Control of the Con
February 22 Changes For	OSTYCES SECIODA IN XIXTOHY NO DOUGHT SECIODA REVISION OF SECIODA REVISION OF SECIODA REVISION OF SECIODA REVISION DEPLICATION REVISION REVISION TANKS REVISION SECIODA	#1,0002 91,0002 91,0002 6ffective Cate 21,0002	The tensing III. A through II
February 22 Changes For	OBLYCAS SOSSOS IN NATORY RE Drug/Class sidenati supp Kinicq Dapinoti Actions Actions Proj/Class Reputa Condic Actions Reputa Condic Reputa Co	#1,000 a #1,	Among III. All And III. A second III. A sec
February 22 Changes For	OBSYCAR SOCIODA IN RECTORY RE RECTORY RE UNIQUE RE RECTOR COMPA RECTOR COMP RE	8/1/0023 5/1/0023 5/1/0023 5/1/0023 5/1/0023 3/1/0023 3/1/0023 3/1/0023 3/1/0023 3/1/0023 3/1/0023 5/1/0023 5/1/0023 5/1/0023 5/1/0023 5/1/0023	A transpired to the control of the c
February 22 Changes For	DEVICED SOCIAL SILVER S	81,0003 81,0003 91,0003	A Terring of Company
Advany 23 Changes for March 24 Chair See	DEVICED SOCIOLO NA CONTROL DE CON	81,0003 81,0003 91,0003 91,0003 91,0003 91,0003 20,0003 20,0003 20,0003 20,0003 20,0003 20,0003 20,0003 20,0003 20,0003 20,0003 20,0003 41,0003 41,0003 41,0003 41,0003	A brancy of A bran
February 22 Changes For	DEVICED - SOCIAL SILVANIA - SO	81,0003 81,0003 91,0003	Among III. Among
Advany 23 Changes for March 24 Chair See	SPICED - SPI	81,0003 81,000	Among III. Book Service Servi
Advany 23 Changes for March 24 Chair See	GRECCE A.	81,0003 81,000	According to Charles Charles
Advany 23 Changes for March 24 Chair See	GPSCCAP MISCOLAP MISCOLA	\$1,0003 \$1,000	Account of the Comment of the Commen
Oberge for March 20 Charge for March 20 Charge for March 20 Charge for F	GRECCE A.	81,0003 81,000	According to Charles Charles
Advany 23 Changes for March 24 Chair See	GROCKER SOCIOLO NO SOCIOLO	812,0083 812	Account of the Comment of the Commen
Advany 23 Changes for March 24 Chair See	GENERAL MANAGEMENT AND ADMINISTRATION OF THE PROPERTY ADMINISTRATION OF THE PROPERTY ADMINISTRATION OF THE PROPERTY ADMINISTRATION OF THE PROPERTY ADMINISTR	812(693) 812(69	Among Info Among
Advany 23 Changes for March 24 Chair See	GENERAL SERVICES AND ADMINISTRATION OF THE PROPERTY OF THE PRO	812(683) 812(683)	Among the Common
Advany 23 Changes for March 24 Chair See	OPICED - STORY OF THE STORY OF	1,000	Acting the Comment of
Advany 23 Changes for March 24 Chair See	SPECIAL STATES OF THE STATES O	1,00001	Action of the Comment
Studenty II Orange for Walso III Carego for Orange for Orange for	SOCIAL STATES AND STAT	1,000	Account of the Comment of the Commen
Studenty II Orange for Walso III Carego for Orange for Orange for	SOCIOLE SERVICE SERVIC	1,00001	Acting the Comment of
Studenty II Orange for Walso III Carego for Orange for Orange for	SPECIAL STATES OF THE STATES O	1,00001, 000000000000000000000000000000	Acting the Comment of
About to Charge No. Ch	SOCIAL STATES OF THE STATES OF	1,00001, 000000000000000000000000000000	Acting the Comment of
Studenty II Orange for Walso III Carego for Orange for Orange for	SOURCE AND ADMINISTRATION OF THE PROPERTY OF T	1,000	Among the March State of Comments of Comme
About to Charge No. Ch	SOCIAL CONTROL OF THE PROPERTY	1,000	Among the Common
About to Charge No. Ch	SOLICIA DE LA CALLES DE LA CALL	1,000	Among the Common of the Common
About to Charge No. Ch	SOCIAL CONTROL OF THE PROPERTY	1,000	Among the Common
Melany 20 Charges for Stock 20 Charges for	SOCIAL DESCRIPTION OF THE PROPERTY OF THE PROP	1,000 pt. 10 pt.	According to the control of the cont
About to Charge No. Ch	SOURCE AND ADMINISTRATION OF THE PROPERTY OF T	1,000 pt. 10 pt.	According to the control of the cont
Studenty 20 Charges for Students for Studen	SOLICIA DE LA CALLANDA DE LA CALLAND	10-00001 10-0001 10	According to the control of the cont
Melany 20 Charges for Stock 20 Charges for	SOUTH AND ADDRESS OF THE PARTY	1,000 pt. 10 pt.	Among the Common of the Common
Studenty 20 Charges for Students for Studen	SOURCE AND ADMINISTRATION OF THE PROPERTY OF T	10-00001 10-0001 10	Among the property of the prop
Makes y 2 Companior Week 22 Companior Week 23	SOCIAL CONTROL OF THE PROPERTY	3-000001 (1990)	According to the control of the cont
Studenty 20 Charges for Students for Studen	SOLICIA DE LA CALLANDA DE LA CALLAND	1,000	According to Ac
Makes y 2 Companior Week 22 Companior Week 23	SOURCE AND ADMINISTRATION OF THE PROPERTY OF T	3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-	According to the control of the cont
Makes y 2 Companior Week 22 Companior Week 23	SOLICIA DE LA CALLANDA DE LA CALLAND	1,000	Among the Common
Makes y 2 Companior Week 22 Companior Week 23	SOUTH AND SECURITY OF THE PROPERTY OF THE PROP	3-000016 1-000016	Account of the control of the contro
Makes y 2 Companior Week 22 Companior Week 23	SOURCE AND ADMINISTRATION OF THE PROPERTY OF T	3-000000000000000000000000000000000000	According to the control of the cont
Manage for West 23 August 16 August	SOUTH AND SOUTH	3-000000000000000000000000000000000000	According to the control of the cont
Manage for Water State S	Application	1,000	According to the control of the cont
Allury (2) Charge for War	SOURCE AND ADMINISTRATION OF THE PROPERTY OF T	1,000	According to the control of the cont
Manage for Water State S	Application	1,000	Acting the Comment of the Secretary of Secre